

/

Claim 4, line 1: Delete “any preceding claim” and insert --claim 1--.

/

Claim 5, line 1: Delete “A” and insert --The--.

/

Claim 6, line 1: Delete “A” and insert --The--.

/

Claim 7, line 1: Delete “A” and insert --The--.

/

Claim 8, line 1: Delete “A” and insert --The--.

/

Claim 9, line 1: Delete “A” and insert --The--.

/

Claim 9, line 1: Delete “or claim 2”.

/

Claim 10, line 1: Rewrite “Nucleic acid” as --A nucleic acid--.

/

Claim 10, lines 1-2: Delete “any preceding claim” and insert --claim 1--.

/

Claim 13, lines 1-2: Delete “any of claims 1 to 9” and insert --claim 1--.

/

Claim 14, line 1: Delete “A” and insert --The--.

/

Claim 16, line 2: Delete “any one of claims 1 to 9 or claim 15” and insert --claim 1--.

/

Claim 17, line 1: Delete “A” and insert --The--.

Claim 19, line 1: Delete "A" and insert --The--.

Claim 19, lines 1-2: Delete "any one of claims 1 to 9 or claim 15" and insert --claim 1--.

Please cancel claims 15 and 18, without prejudice.

Please add the following new claims 20-24:

1 20. The conjugate according to claim 7, wherein the second region is a histone
2 protein.

1 21. The conjugate according to claim 2, wherein the second region comprises an
2 NOI.

1 22. A conjugate prepared by a method comprising the steps:
2 (i) culturing a host cell according to claim 12 under conditions which provide for the
3 expression of the conjugate within the host cell; and
4 (ii) recovering the conjugate by affinity purification under non-denaturing conditions.

1 23. The conjugate prepared according to claim 22, wherein the conjugate comprises
2 an amino acid tail that binds to an immobilised substrate.

1 24. A method for the treatment or prevention of a condition selected from the group
2 consisting of cancer, genetic disease, bacterial infection and viral infection, said method
3 comprising administering an effective amount of a conjugate of claim 1 to a person or animal
4 in need of such treatment, wherein the second region of the conjugate comprises a moiety
5 useful in treating or preventing said condition.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606

DRP/sl

Attachment: Abstract of the Disclosure